News · FDA and regulation

FDA Panel Recommends Six of Seven Peptides for Compounding, Overriding Its Own Scientists

Across 23-24 July the Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A bulks list against unanimous staff advice, rejecting only emideltide. The votes are non-binding, each is indication-specific, and nothing is lawful yet.

Event date 2026-07-23 · Published 2026-07-25 · EV-1301

What happened

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8–6 with one abstention to recommend BPC-157, KPV and TB-500 for inclusion on the 503A bulk drug substances list, and 7–5 with two abstentions for MOTS-c.

All four recommendations went against the FDA's own staff reviewers, who had recommended against every one of the seven substances under review across the two-day meeting. Reporters present described an audible reaction in the room when the first tally was read.

The committee reconvened on 24 July to consider the remaining three. The full two-day tally is below.

What FDA scientists actually said

The agency's briefing package cited a lack of evidence supporting the effectiveness of BPC-157 for ulcerative colitis, the indication under review. For TB-500, staff reported being unable to identify a single human clinical study.

A more basic objection surfaced during the meeting: without universally accepted chemical definitions for these substances, identity, quality and comparability are unclear — which undermines any assessment of safety or effectiveness before the efficacy question is even reached. One FDA official asked plainly what BPC-157 is, noting that different parties describe it differently.

Who voted which way

On BPC-157, KPV and TB-500 the split was identical each time. All eight of the committee's newly added temporary members voted in favour. Six other members voted against, and one abstained.

That composition is the story within the story. A committee that adds eight temporary members who then vote as a bloc against the standing membership and against agency staff is producing a result driven by who was seated rather than by what the evidence showed. The committee has separately faced scrutiny over members with conflicts of interest.

Members voting against cited insufficient evidence of efficacy. One warned that although the vote is not an FDA approval, consumers would perceive it as an endorsement. That has already happened.

Day two: six of seven recommended

The committee reconvened on 24 July and recommended two of the three remaining peptides.

Vote format: yes–no–abstain. Docket FDA-2025-N-6895. Reported vote counts differ slightly between outlets for epitalon; we have logged both.

Emideltide was the single rejection, and it is instructive. David Pope, chief pharmacy officer at XiFin Pharmacy Solution, had voted with the majority on the earlier peptides and moved to dissent here, citing concern about potentially dangerous downstream consequences. A committee that recommended six substances on thin evidence still drew a line at one — which suggests the earlier votes were not purely procedural.

The detail almost every summary omits: these are indication-specific

None of these votes recommends blanket compounding. Each substance was reviewed against a specific proposed use, and that is what any eventual listing would cover.

BPC-157 was reviewed for ulcerative colitis — not for tendon repair, joint recovery or the athletic uses that drive almost all of its consumer demand. TB-500 was reviewed for wound healing. A pharmacy compounding BPC-157 for a patient's knee would not be operating within the reviewed indication even if the substance is eventually listed.

That gap between the reviewed indication and the marketed use is where the next round of enforcement letters will land, and it is entirely absent from the coverage celebrating the vote.

MOTS-c was reviewed for obesity

One of the six carries direct relevance to this publication. MOTS-c was reviewed for obesity and osteoporosis, and recommended 7–5 with two abstentions.

It has nothing resembling the evidence base behind the approved obesity drugs. Tirzepatide has SURMOUNT-1 through SURMOUNT-5, SURPASS-CVOT and SUMMIT — tens of thousands of randomised participants with registry identifiers and published protocols. NPR's summary of the meeting is blunt about the comparison: all seven substances lack the large, well-controlled human trials required to establish safety and effectiveness.

So a lawful compounding channel may open for an obesity peptide with no phase 3 programme, in the same year the FDA proposed closing the 503B bulk channel for tirzepatide and semaglutide, which have several. Those two proceedings are not connected procedurally. Read together they are hard to reconcile.

The fact that reframes the whole story

All seven substances came off the FDA's Category 2 list — the register of substances that may not be compounded — on 23 April 2026. That reclassification is what made this review possible.

So the July votes were never a re-ban risk. The downside was the status quo; the only question was whether a new lawful channel opens. Coverage framing this as peptides "surviving" a regulatory threat has the direction backwards.

Under section 503A, a compounded drug is exempt from FDA approval and manufacturing requirements only if the bulk substance complies with a USP monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List. For these seven, the third route is the only one available — which is why the list matters so much and why the vote drew the attention it did.

The three legal events being treated as one

This is the part most coverage has collapsed, and it decides what is lawful today.

1. Removal from Category 2 — the list of substances FDA has flagged with significant safety concerns.
2. A PCAC recommendation — what happened on 23 July. Non-binding.
3. Placement on the Category 1 compoundable list — requires formal notice-and-comment rulemaking, commonly 8 to 12 months.

Only the third makes compounding lawful. The FDA is not bound by the recommendation and has declined to follow this committee before. In 2023 the agency reviewed a batch of popular peptides and declined to add them, stating they may present significant safety risks — the decision that pushed these compounds into the grey market they have occupied since.

What changes for you today

Legally, nothing. BPC-157, KPV, TB-500 and MOTS-c remain unapproved and off the sanctioned compounding pathway. Products sold under "research use only" labelling are in exactly the position they were in on 22 July.

What changed is the probability of a future change. That is a real shift and it is not the same thing, and the gap between them is where sellers will operate for the next several months.

Expect marketing over the coming weeks describing these peptides as FDA-backed, newly permitted, or approaching approval. None of that is accurate. A recommendation from an advisory committee that overrode its own agency's scientists is a weaker signal than an ordinary recommendation, not a stronger one.

If the FDA does adopt it

Compounding would require a prescription from a licensed prescriber and dispensing by a licensed pharmacy, which adds consultation cost and adds regulatory oversight that the grey market has none of. Compounded drugs are generally not covered by insurance, so patients would pay out of pocket.

That would be a genuine improvement in patient safety over the current situation, whatever one thinks of the evidence. A patient obtaining a peptide through a prescriber and a licensed pharmacy is in a materially better position than one buying research-labelled product online.

Our correction

We published peptide pages on 24 July stating that briefing documents recommended against inclusion and that the regulatory direction was toward closing the compounding route. The staff recommendation was accurate; our inference from it was not, and the committee had already voted the other way.

That is logged as COR-005 with the previous wording preserved. Describing a live regulatory process by its most recent document, rather than by its actual state, is the specific error — and it is worth naming because a great deal of coverage this week is making it in the opposite direction.

If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.

Questions readers actually ask